To All: Does it seem strange to anyone else that BXM announced that data from this study was presented but then did not include any data or results in the press release? Any ideas? Lisa
************************************************************
Wednesday September 22, 8:00 am Eastern Time
Company Press Release
SOURCE: Biomatrix, Inc.
Twelve Month Data Reported from Clinical Study of Synvisc(R) in Management of Osteoarthritis of the Knee
Initial Data Presented at OARSI '99 Meeting in Vienna
RIDGEFIELD, N.J., Sept. 22 /PRNewswire/ -- Biomatrix, Inc. (NYSE: BXM - news) today reported that data from a randomized controlled clinical trial analyzing the clinical effectiveness and cost effectiveness of the use of Synvisc© for the management of osteoarthritis of the knee was presented during a Satellite Symposium at the annual OARSI (Osteoarthritis Research Society International) Congress on September 17, 1999 in Vienna, Austria. Synvisc© is the company's novel therapy for osteoarthritis of the knee. This recently completed trial was designed, managed and reported by an independent academic steering committee of international opinion leaders in compliance with published guidelines for pharmacoeconomic studies. Fourteen clinical investigators, specialists in both rheumatology and orthopedics, conducted the study over the past two years with patients from all across Canada.
Dr. Endre Balazs, Biomatrix' chief executive officer and chief scientific officer, stated, ``We are grateful to the steering committee for their outstanding efforts in carrying out this detailed and comprehensive evaluation of the use of Synvisc for the management of osteoarthritis of the knee. We look forward to the release of full trial results from this landmark study in the peer reviewed literature. This data will demonstrate the value of Synvisc and will be important to patients and healthcare providers.'
Synvisc is marketed in the USA, most countries of the European Economic Area, and certain countries in Latin America and Asia. Biomatrix has contracts to market Synvisc in over 90 countries through marketing and distribution agreements with a number of large multi-national healthcare companies, and through its wholly-owned subsidiaries. Wyeth-Ayerst Laboratories has distribution rights and markets Synvisc in the USA and certain European and Middle Eastern countries; Boehringer-Ingelheim in France; Rhone-Poulenc Rorer in Canada; F. Hoffmann-La Roche Ltd. in Sweden and South Africa; Novartis Pharma AG throughout Latin America; and Bayer AG in Australia, New Zealand and certain countries in Asia.
Biomatrix developed and manufactures several other viscoelastic medical therapeutics. Hylaform© is an injectable viscoelastic hylan gel treatment for the correction of facial wrinkles and depressed scars. It is marketed in 23 countries by Collagen Aesthetics, Inc. (now Inamed Corp., OTC Bulletin Board: IMDC). Gelvisc© Vet is an elastoviscous hylan product for the treatment of arthritis in veterinary medicine that is distributed by Boehringer-Ingelheim in France and Equinord in Sweden. Biomatrix' Hylashield© products are viscoelastic therapeutics for the protection of the surface of the eye from noxious environmental conditions and are distributed in Canada by I-MED Pharma Inc. Biomatrix also manufactures nine patented elastoviscous intermediates for the skin care industry.
Biomatrix, Inc., headquartered in Ridgefield, New Jersey is an international biomedical company that develops, manufactures and commercializes elastoviscous products made from proprietary biological polymers called hylans, used in therapeutic medical applications and in skin care products.
Certain statements in this press release are forward-looking statements that involve risks and uncertainties including, but not limited to, the regulatory approval process, obtaining and enforcing patents, reimbursement by private health care providers, manufacturing capabilities, projected earnings and financial results, growing product demand, product liability, inventory levels of our marketing partners, future product development, and other risks detailed in Biomatrix' reports filed under the Securities Exchange Act, including Forms 10-Q and Biomatrix' annual report on Form 10-K for the year ended December 31, 1998. For more information on Biomatrix, please visit the Company's web site at biomatrix.com.
Editor's note: Synvisc©, Hylaform©, Gelvisc© Vet and Hylashield© are registered trademarks of Biomatrix, Inc.
SOURCE: Biomatrix, Inc. |
